PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing
PAVmed (Nasdaq: PAVM) announced that its subsidiary Veris Health has completed a $2.5 million private placement equity financing. The financing involved selling Veris Health common stock at $1.40 per share, with a pre-money valuation of $35 million.
Investors received warrants to purchase additional shares at $1.40 per share, callable within 60 days of FDA clearance. This funding follows a previous $2.4 million financing earlier this year. The proceeds will support the development of Veris' implantable physiological monitor through FDA clearance, expected in 2026, and general corporate purposes.
PAVmed (Nasdaq: PAVM) ha annunciato che la sua controllata Veris Health ha completato un finanziamento azionario tramite collocamento privato da 2,5 milioni di dollari. L'operazione ha previsto la vendita di azioni ordinarie di Veris Health a 1,40 dollari per azione, con una valutazione pre-money di 35 milioni di dollari.
Gli investitori hanno ricevuto warrant per acquistare ulteriori azioni a 1,40 dollari ciascuna, esercitabili entro 60 giorni dall'approvazione FDA. Questo finanziamento segue un precedente finanziamento da 2,4 milioni di dollari realizzato all'inizio di quest'anno. I proventi saranno utilizzati per sostenere lo sviluppo del monitor fisiologico impiantabile di Veris fino all'approvazione FDA, prevista per il 2026, e per scopi aziendali generali.
PAVmed (Nasdaq: PAVM) anunció que su subsidiaria Veris Health ha completado una financiación de capital mediante colocación privada por 2.5 millones de dólares. La financiación consistió en la venta de acciones ordinarias de Veris Health a 1.40 dólares por acción, con una valoración pre-money de 35 millones de dólares.
Los inversores recibieron warrants para comprar acciones adicionales a 1.40 dólares cada una, ejercitables dentro de los 60 días posteriores a la aprobación de la FDA. Esta financiación sigue a una anterior ronda de 2.4 millones de dólares realizada a principios de este año. Los fondos se destinarán a apoyar el desarrollo del monitor fisiológico implantable de Veris hasta la aprobación de la FDA, prevista para 2026, y a fines corporativos generales.
PAVmed (나스닥: PAVM)는 자회사 Veris Health가 250만 달러 규모의 사모주식 발행을 완료했다고 발표했습니다. 이번 자금 조달은 Veris Health 보통주를 주당 1.40달러에 판매했으며, 사전 가치 평가액은 3500만 달러였습니다.
투자자들은 FDA 승인 후 60일 이내에 행사가 가능한 주당 1.40달러의 추가 주식 매수 워런트를 받았습니다. 이번 자금 조달은 올해 초 진행된 240만 달러 자금 조달에 이은 것입니다. 조달된 자금은 2026년으로 예상되는 FDA 승인까지 Veris의 이식형 생리 모니터 개발과 일반 회사 운영 자금으로 사용될 예정입니다.
PAVmed (Nasdaq : PAVM) a annoncé que sa filiale Veris Health a finalisé un financement en actions par placement privé de 2,5 millions de dollars. Ce financement a consisté en la vente d’actions ordinaires de Veris Health à 1,40 dollar par action, avec une valorisation pré-money de 35 millions de dollars.
Les investisseurs ont reçu des bons de souscription leur permettant d’acheter des actions supplémentaires à 1,40 dollar chacune, exerçables dans les 60 jours suivant l’autorisation de la FDA. Ce financement fait suite à une précédente levée de fonds de 2,4 millions de dollars réalisée plus tôt cette année. Les fonds serviront à soutenir le développement du moniteur physiologique implantable de Veris jusqu’à l’autorisation de la FDA, prévue en 2026, ainsi qu’à des fins générales d’entreprise.
PAVmed (Nasdaq: PAVM) gab bekannt, dass seine Tochtergesellschaft Veris Health eine Private Placement Finanzierung in Höhe von 2,5 Millionen US-Dollar abgeschlossen hat. Die Finanzierung umfasste den Verkauf von Veris Health Stammaktien zu 1,40 US-Dollar pro Aktie bei einer Pre-Money-Bewertung von 35 Millionen US-Dollar.
Investoren erhielten Warrants zum Kauf zusätzlicher Aktien zu 1,40 US-Dollar pro Aktie, ausübbar innerhalb von 60 Tagen nach FDA-Zulassung. Diese Finanzierung folgt auf eine vorherige 2,4 Millionen US-Dollar Finanzierung Anfang dieses Jahres. Die Erlöse werden die Entwicklung des implantierbaren physiologischen Monitors von Veris bis zur FDA-Zulassung, die für 2026 erwartet wird, und allgemeine Unternehmenszwecke unterstützen.
- Secured $2.5 million in gross and net proceeds from private placement
- Attractive company valuation of $35 million pre-money
- Additional funding potential through warrant exercises post-FDA clearance
- Previous successful financing of $2.4 million completed earlier this year
- Clear pathway to FDA clearance expected in 2026
- Potential dilution from warrant exercises
- FDA clearance not expected until 2026, indicating long development timeline
Insights
Veris Health's $2.5M financing at $35M valuation strengthens its path to FDA clearance of implantable monitor in 2026.
This $2.5 million financing for Veris Health, PAVmed's subsidiary, represents a strategic capital infusion at a noteworthy $35 million pre-money valuation. Coming after a $2.4 million raise earlier this year, this brings Veris's recent funding to $4.9 million - a substantial sum for advancing its implantable physiological monitor through regulatory clearance.
The valuation metrics are particularly telling. At $1.40 per share with warrant coverage, investors have valued this early-stage medical technology asset at a premium, suggesting confidence in both the technology and management's execution capabilities. The callable warrant structure cleverly aligns additional capital infusion with FDA clearance milestones, potentially bringing in significant additional funding precisely when commercialization expenses will increase.
The capital efficiency appears strong here. Management indicates this funding should carry Veris through FDA clearance expected in 2026 and into commercial launch - a critical inflection point for value creation. For PAVmed shareholders, this subsidiary financing minimizes parent company dilution while advancing a potentially valuable asset.
The implantable monitor represents a differentiated approach in the cancer care space, with potential recurring revenue opportunities through the integrated Veris Cancer Care Platform. This combination of hardware and software creates a higher-value ecosystem than either component alone, potentially justifying the premium valuation. For a medical device company targeting the oncology space, this funding structure and pathway to commercialization demonstrates savvy capital planning and clear regulatory strategy.
Private placement yields
Veris sold shares of its common stock at
"This financing, at an attractive valuation, reflects strong investor confidence in Veris' commercial potential and represents an important milestone for both PAVmed and Veris," said Lishan Aklog, M.D., Chairman and CEO of PAVmed and Executive Chairman of Veris Health. "Veris is now sufficiently capitalized to fund development of its implantable physiological monitor through FDA clearance and subsequent commercial launch. The monitor—designed to enhance personalized care in conjunction with the Veris Cancer Care Platform—will serve as a key commercial differentiator."
About Veris Health
Veris Health Inc. is a digital health company whose lead product, the Veris Cancer Care Platform, is a comprehensive digital care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.
Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via an embedded cellular connection. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted in combination with a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance.
Cancer centers and oncology centers interested in learning more about Veris and the Veris Platform, please visit www.verishealth.com to contact a company representative.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its other subsidiary (in addition to Veris), Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-subsidiary-veris-health-completes-2-5-million-direct-equity-financing-302489600.html
SOURCE PAVmed Inc.
FAQ
How much funding did Veris Health, PAVmed's subsidiary, raise in its latest financing round?
What is the purpose of Veris Health's recent $2.5M funding?
What is the warrant structure in PAVM's Veris Health financing?
When is Veris Health expecting FDA clearance for its physiological monitor?
How much total funding has Veris Health secured in 2025?
